Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malaria

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    April 2018
  1. AN SJ, Scaria PV, Chen B, Barnafo E, et al
    Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    Vaccine. 2018 Apr 19. pii: S0264-410X(18)30518.
    PubMed     Text format     Abstract available


    March 2018
  2. NLINWE ON, Kusi KA, Adu B, Sedegah M, et al
    T-cell responses against Malaria: Effect of parasite antigen diversity and relevance for vaccine development.
    Vaccine. 2018 Mar 21. pii: S0264-410X(18)30368.
    PubMed     Text format     Abstract available


    February 2018
  3. SIMON N, Friedrich O, Kappes B
    Quantification of human complement factor H binding to asexual malaria blood stages by an enzyme-linked immunosorbent assay.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30153.
    PubMed     Text format     Abstract available


  4. NIELSEN CM, Vekemans J, Lievens M, Kester KE, et al
    RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype.
    Vaccine. 2018 Feb 10. pii: S0264-410X(18)30142.
    PubMed     Text format     Abstract available


    November 2017
  5. ROESTENBERG M, Mordmuller B, Ockenhouse C, Mo A, et al
    The frontline of controlled human malaria infections: A report from the controlled human infection models Workshop in Leiden University Medical Centre 5 May 2016.
    Vaccine. 2017 Nov 16. pii: S0264-410X(17)31522.
    PubMed     Text format     Abstract available


    October 2017
  6. SHIRATSUCHI T, Rai U, Kaneko I, Zhang M, et al
    A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31474.
    PubMed     Text format     Abstract available


  7. PERRAUT R, Varela ML, Joos C, Diouf B, et al
    Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria.
    Vaccine. 2017 Oct 14. pii: S0264-410X(17)31391.
    PubMed     Text format     Abstract available


    September 2017
  8. SIRIMA SB, Durier C, Kara L, Houard S, et al
    Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Vaccine. 2017 Sep 22. pii: S0264-410X(17)31247.
    PubMed     Text format     Abstract available


  9. VENKATRAMAN N, Anagnostou N, Bliss C, Bowyer G, et al
    Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M.
    Vaccine. 2017 Sep 20. pii: S0264-410X(17)31248.
    PubMed     Text format     Abstract available


    June 2017
  10. GENITO CJ, Beck Z, Phares TW, Kalle F, et al
    Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Vaccine. 2017 Jun 5. pii: S0264-410X(17)30729.
    PubMed     Text format     Abstract available


    May 2017
  11. SINGH SK, Thrane S, Janitzek CM, Nielsen MA, et al
    Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Vaccine. 2017 May 31. pii: S0264-410X(17)30690.
    PubMed     Text format     Abstract available


  12. ZHU D, Wu Y, McClellan H, Dai W, et al
    Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel(R).
    Vaccine. 2017;35:3232-3238.
    PubMed     Text format     Abstract available


  13. GBEDANDE K, Fievet N, Viwami F, Ezinmegnon S, et al
    Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae.
    Vaccine. 2017 May 17. pii: S0264-410X(17)30635.
    PubMed     Text format     Abstract available


  14. FONSECA JA, McCaffery JN, Kashentseva E, Singh B, et al
    A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30554.
    PubMed     Text format     Abstract available


  15. LI X, Huang J, Kawamura A, Funakoshi R, et al
    Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30578.
    PubMed     Text format     Abstract available


    April 2017
  16. CHATTOPADHYAY R, Pratt D
    Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective.
    Vaccine. 2017 Apr 18. pii: S0264-410X(17)30406.
    PubMed     Text format    



  17. Malaria vaccine: WHO position paper, January 2016 - Recommendations.
    Vaccine. 2017 Apr 3. pii: S0264-410X(16)30982.
    PubMed     Text format     Abstract available


    March 2017
  18. LUO K, Zavala F, Gordy J, Zhang H, et al
    Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
    Vaccine. 2017 Mar 22. pii: S0264-410X(17)30369.
    PubMed     Text format     Abstract available


  19. FORD T, Wenden C, Mbekeani A, Dally L, et al
    Cryopreservation-related loss of antigen-specific IFNgamma producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.
    Vaccine. 2017 Mar 9. pii: S0264-410X(17)30241.
    PubMed     Text format     Abstract available


  20. SETH L, Bingham Ferlez KM, Kaba SA, Musser DM, et al
    Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.
    Vaccine. 2017 Mar 5. pii: S0264-410X(17)30243.
    PubMed     Text format     Abstract available


    January 2017
  21. ANDERSSON AC, Resende M, Salanti A, Nielsen MA, et al
    Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.
    Vaccine. 2017 Jan 25. pii: S0264-410X(17)30033.
    PubMed     Text format     Abstract available


  22. KANOI BN, Takashima E, Morita M, White MT, et al
    Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda.
    Vaccine. 2017 Jan 12. pii: S0264-410X(17)30003.
    PubMed     Text format     Abstract available


  23. MILLIGAN P, Flach C, Theisen M
    Efficacy of the GMZ2 malaria vaccine in African children.
    Vaccine. 2017;35:202.
    PubMed     Text format    


  24. EJIGU DA
    When should a time at risk start in efficacy malaria vaccine trials?
    Vaccine. 2017;35:201.
    PubMed     Text format    


  25. GESSNER BD, Knobel DL, Conan A, Finn A, et al
    Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine?
    Vaccine. 2017 Jan 5. pii: S0264-410X(17)30001.
    PubMed     Text format     Abstract available


    December 2016
  26. MATTHIESSEN L, Lang H, Klimathianaki M, Hanrahan F, et al
    European strategy for vaccine development against infectious diseases.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)30952.
    PubMed     Text format     Abstract available


  27. PEHRSON C, Heno KK, Adams Y, Resende M, et al
    Comparison of functional assays used in the clinical development of a placental malaria vaccine.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31235.
    PubMed     Text format     Abstract available


    November 2016
  28. DATTA D, Bansal GP, Gerloff DL, Ellefsen B, et al
    Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Vaccine. 2016 Nov 29. pii: S0264-410X(16)31143.
    PubMed     Text format     Abstract available


  29. GALACTIONOVA K, Tediosi F, Camponovo F, Smith TA, et al
    Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
    Vaccine. 2016 Nov 24. pii: S0264-410X(16)31103.
    PubMed     Text format     Abstract available


    October 2016
  30. BRICKLEY EB, Coulibaly M, Gabriel EE, Healy SA, et al
    Utilizing direct skin feeding assays for development of vaccines that interrupt malaria transmission: A systematic review of methods and case study.
    Vaccine. 2016 Oct 24. pii: S0264-410X(16)30945.
    PubMed     Text format     Abstract available


    September 2016
  31. SPEARMAN P, Mulligan M, Anderson EJ, Shane AL, et al
    A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.
    Vaccine. 2016 Sep 30. pii: S0264-410X(16)30855.
    PubMed     Text format     Abstract available


  32. NTEGE EH, Arisue N, Ito D, Hasegawa T, et al
    Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Vaccine. 2016 Sep 28. pii: S0264-410X(16)30841.
    PubMed     Text format     Abstract available


    August 2016
  33. LI X, Huang J, Zhang M, Funakoshi R, et al
    Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice.
    Vaccine. 2016 Aug 5. pii: S0264-410X(16)30663.
    PubMed     Text format     Abstract available


    July 2016
  34. SIRIMA SB, Mordmuller B, Milligan P, Ngoa UA, et al
    A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
    Vaccine. 2016 Jul 28. pii: S0264-410X(16)30625.
    PubMed     Text format     Abstract available


  35. PARSONS E, Epstein J, Sedegah M, Villasante E, et al
    Decrease in circulating CD25hiFoxp3+ regulatory T cells following vaccination with the candidate malaria vaccine RTS,S.
    Vaccine. 2016 Jul 18. pii: S0264-410X(16)30581.
    PubMed     Text format     Abstract available


    May 2016
  36. BLAGBOROUGH AM, Musiychuk K, Bi H, Jones RM, et al
    Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Vaccine. 2016 May 10. pii: S0264-410X(16)30290.
    PubMed     Text format     Abstract available


    March 2016
  37. BALDWIN SL, Roeffen W, Singh SK, Tiendrebeogo RW, et al
    Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
    Vaccine. 2016 Mar 16. pii: S0264-410X(16)00327.
    PubMed     Text format     Abstract available


  38. BIRKETT AJ
    Status of vaccine research and development of vaccines for malaria prepared for WHO PD-VAC.
    Vaccine. 2016 Mar 15. pii: S0264-410X(16)00294.
    PubMed     Text format     Abstract available


    February 2016
  39. GONCALVES BP, Prevots DR, Kabyemela E, Fried M, et al
    Preparing for future efficacy trials of severe malaria vaccines.
    Vaccine. 2016 Feb 25. pii: S0264-410X(16)00234.
    PubMed     Text format     Abstract available


    December 2015
  40. KPANAKE L, Sorum PC, Mullet E
    The potential acceptability of infant vaccination against malaria: A mapping of parental positions in Togo.
    Vaccine. 2015 Dec 17. pii: S0264-410X(15)01780.
    PubMed     Text format     Abstract available


    November 2015
  41. KANGOYE DT, Mensah VA, Murungi LM, Nkumama I, et al
    Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity.
    Vaccine. 2015 Nov 2. pii: S0264-410X(15)01473.
    PubMed     Text format     Abstract available


    October 2015
  42. SAUERWEIN RW, Richie TL
    Malaria vaccines getting close to clinical reality.
    Vaccine. 2015 Oct 27. pii: S0264-410X(15)01548.
    PubMed     Text format    


  43. LAPKE N, Tartz S, Lee KH, Jacobs T, et al
    The application of anti-Toso antibody enhances CD8 T cell responses in experimental malaria vaccination and disease.
    Vaccine. 2015 Oct 24. pii: S0264-410X(15)01494.
    PubMed     Text format     Abstract available


  44. EWER KJ, Sierra-Davidson K, Salman AM, Illingworth JJ, et al
    Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".
    Vaccine. 2015 Oct 14. pii: S0264-410X(15)01384.
    PubMed     Text format     Abstract available


  45. WHITE MT, Verity R, Churcher TS, Ghani AC, et al
    Vaccine approaches to malaria control and elimination: Insights from mathematical models.
    Vaccine. 2015 Oct 14. pii: S0264-410X(15)01389.
    PubMed     Text format     Abstract available


  46. OUATTARA A, Barry AE, Dutta S, Remarque EJ, et al
    Designing malaria vaccines to circumvent antigen variability.
    Vaccine. 2015 Oct 13. pii: S0264-410X(15)01414.
    PubMed     Text format     Abstract available


  47. NAHRENDORF W, Scholzen A, Sauerwein RW, Langhorne J, et al
    Cross-stage immunity for malaria vaccine development.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01388.
    PubMed     Text format     Abstract available


  48. PATARROYO ME, Patarroyo MA, Pabon L, Curtidor H, et al
    Immune protection-inducing protein structures (IMPIPS) against malaria: the weapons needed for beating Odysseus.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01412.
    PubMed     Text format     Abstract available


  49. BIRKETT AJ
    Building an effective malaria vaccine pipeline to address global needs.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01415.
    PubMed     Text format     Abstract available


  50. RICHIE TL, Billingsley PF, Sim BK, Epstein JE, et al
    Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01386.
    PubMed     Text format     Abstract available


  51. FRIED M, Duffy PE
    Designing a VAR2CSA-based vaccine to prevent placental malaria.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01422.
    PubMed     Text format     Abstract available


  52. BIJKER EM, Borrmann S, Kappe SH, Mordmuller B, et al
    Novel approaches to whole sporozoite vaccination against malaria.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01385.
    PubMed     Text format     Abstract available


  53. DRAPER SJ, Angov E, Horii T, Miller LH, et al
    Recent advances in recombinant protein-based malaria vaccines.
    Vaccine. 2015 Oct 9. pii: S0264-410X(15)01383.
    PubMed     Text format     Abstract available


  54. WU Y, Narum DL, Fleury S, Jennings G, et al
    Particle-based platforms for malaria vaccines.
    Vaccine. 2015 Oct 9. pii: S0264-410X(15)01387.
    PubMed     Text format     Abstract available


  55. TENEZA-MORA N, Lumsden J, Villasante E
    A malaria vaccine for travelers and military personnel: Requirements and top candidates.
    Vaccine. 2015 Oct 9. pii: S0264-410X(15)01413.
    PubMed     Text format     Abstract available


    September 2015
  56. VIEBIG NK, D'Alessio F, Draper SJ, Sim BK, et al
    Workshop report: Malaria vaccine development in Europe-preparing for the future.
    Vaccine. 2015 Sep 30. pii: S0264-410X(15)01350.
    PubMed     Text format     Abstract available


  57. KASLOW DC, Biernaux S
    RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.
    Vaccine. 2015 Sep 29. pii: S0264-410X(15)01337.
    PubMed     Text format     Abstract available


  58. DAVIES DH, Duffy P, Bodmer JL, Felgner PL, et al
    Large screen approaches to identify novel malaria vaccine candidates.
    Vaccine. 2015 Sep 28. pii: S0264-410X(15)01335.
    PubMed     Text format     Abstract available


  59. MUELLER I, Shakri AR, Chitnis CE
    Development of vaccines for Plasmodium vivax malaria.
    Vaccine. 2015 Sep 28. pii: S0264-410X(15)01336.
    PubMed     Text format     Abstract available


  60. STANISIC DI, Good MF
    Whole organism blood stage vaccines against malaria.
    Vaccine. 2015 Sep 28. pii: S0264-410X(15)01333.
    PubMed     Text format     Abstract available


  61. SAUERWEIN RW, Bousema T
    Transmission blocking malaria vaccines: Assays and candidates in clinical development.
    Vaccine. 2015 Sep 24. pii: S0264-410X(15)01213.
    PubMed     Text format     Abstract available


    August 2015
  62. HOFFMAN SL, Vekemans J, Richie TL, Duffy PE, et al
    The march toward malaria vaccines.
    Vaccine. 2015 Aug 28. pii: S0264-410X(15)01070.
    PubMed     Text format     Abstract available


  63. KUMAR R, Ray PC, Datta D, Bansal GP, et al
    Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
    Vaccine. 2015 Aug 20. pii: S0264-410X(15)01147.
    PubMed     Text format     Abstract available


  64. DUNACHIE S, Hill AV, Fletcher HA
    Profiling the host response to malaria vaccination and malaria challenge.
    Vaccine. 2015 Aug 6. pii: S0264-410X(15)01116.
    PubMed     Text format     Abstract available


  65. DUNACHIE S, Berthoud T, Hill AV, Fletcher HA, et al
    Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.
    Vaccine. 2015 Aug 6. pii: S0264-410X(15)01065.
    PubMed     Text format     Abstract available


    July 2015
  66. HO MM, Baca-Estrada M, Conrad C, Karikari-Boateng E, et al
    Implementation workshop of WHO guidelines on evaluation of malaria vaccines: Current regulatory concepts and issues related to vaccine quality, Pretoria, South Africa 07 Nov 2014.
    Vaccine. 2015 Jul 9. pii: S0264-410X(15)00924.
    PubMed     Text format     Abstract available


    April 2015
  67. TACHIBANA M, Suwanabun N, Kaneko O, Iriko H, et al
    Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
    Vaccine. 2015;33:1901-8.
    PubMed     Text format     Abstract available


  68. SINGH SK, Roeffen W, Andersen G, Bousema T, et al
    A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies.
    Vaccine. 2015;33:1981-6.
    PubMed     Text format     Abstract available


    January 2015
  69. SALA KA, Nishiura H, Upton LM, Zakutansky SE, et al
    The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro.
    Vaccine. 2015;33:437-45.
    PubMed     Text format     Abstract available


    December 2014
  70. LULE SA, Mawa PA, Nkurunungi G, Nampijja M, et al
    Factors associated with tuberculosis infection, and with anti-mycobacterial immune responses, among five year olds BCG-immunised at birth in Entebbe, Uganda.
    Vaccine. 2014 Dec 18. pii: S0264-410X(14)01643.
    PubMed     Text format     Abstract available


    July 2014
  71. UMEH R, Oguche S, Oguonu T, Pitmang S, et al
    Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: A randomized, double-blind, lot-to-lot consistency trial.
    Vaccine. 2014 Jul 28. pii: S0264-410X(14)01019.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malaria is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: